Skin microbiome normalizes under tralokinumab therapy

Atopic dermatitis is associated with dysbiosis of the cutaneous microbiome. Characteristic is reduced bacterial diversity, with Staphylococcus aureus often being the dominant bacterial genus. In a recent study, it was shown that the proportion of Staphylococcus aureus is reduced in the course of therapy with tralokinumab. This was accompanied by an increase in the diversity of the skin microbiome.